scispace - formally typeset
W

W. Gregory Alvord

Researcher at National Institutes of Health

Publications -  84
Citations -  7572

W. Gregory Alvord is an academic researcher from National Institutes of Health. The author has contributed to research in topics: Virus & Reverse transcriptase. The author has an hindex of 39, co-authored 84 publications receiving 6936 citations. Previous affiliations of W. Gregory Alvord include Science Applications International Corporation & Leidos.

Papers
More filters
Journal ArticleDOI

The DAVID Gene Functional Classification Tool: a novel biological module-centric algorithm to functionally analyze large gene lists

TL;DR: The DAVID Gene Functional Classification Tool uses a novel agglomeration algorithm to condense a list of genes or associated biological terms into organized classes of related genes or biology, called biological modules, for efficient interpretation of gene lists in a network context.
Journal ArticleDOI

Residual NADPH oxidase and survival in chronic granulomatous disease.

TL;DR: The production of residual ROI is predicted by the specific NADPH oxidase mutation, regardless of the specific gene affected, and it is a predictor of survival in patients with chronic granulomatous disease.
Journal ArticleDOI

Nature, Position, and Frequency of Mutations Made in a Single Cycle of HIV-1 Replication

TL;DR: An efficient system is developed, based on existing technology, to analyze the mutations that arise in an HIV-1 vector in a single cycle of replication, and the mutation rate was not affected by the orientation of lacZα, but the sites favored for mutations depended on which strand of LacZα was present in the viral RNA.
Journal ArticleDOI

Flavopiridol Induces Apoptosis of Normal Lymphoid Cells, Causes Immunosuppression, and Has Potent Antitumor Activity In Vivo Against Human Leukemia and Lymphoma Xenografts

TL;DR: It is concluded that flavopiridol greatly influences apoptosis in both normal and malignant hematopoietic tissues, and provides compelling evidence for the use of flavopirs in human hematologic malignancies.